Recent clinical evidence suggests that GLP-1–based medicines such as semaglutide (Ozempic) and tirzepatide (Mounjaro) do more than shrink waistlines. Researchers are now linking these drugs to lower rates of stroke and heart problems, prompting fresh interest from clinicians, patients and health reporters alike. Growing body of research shows cardiovascular benefit …